Integrated Wellness
Member Login

The visual research atlas

The science.
Made clearer.

Clear explanations first. Scientific detail only when you want it. Explore a molecule, what it interacts with, what researchers measured and what they still don’t know.

Illustrated overview + interactive explanations

Education. Research. Perspective. For learning about research only. These simple maps are not medical advice or instructions for treatment. They do not tell you what to take, how much to take, or what to combine. Showing a possible biological process does not prove that it helps people.

Human outcomesHuman trials in specific groups

What does acting on two cell receivers mean?

Tirzepatide acts on two connected hormone systems. This map explains the idea without suggesting twice the benefit.

How strong is the evidence?

Stronger human evidence · specific uses

  1. Limited evidence
  2. Early research
  3. Human research
  4. Human outcomesCurrent category

Controlled human trials support specific outcomes in the people studied. That does not prove every claimed use, remove risks or make a treatment right for everyone.

For this research: Two targets do not mean twice the benefit, or that medicines should be combined.

An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.

CONCEPTUAL MAP / NOT TO SCALE

Select a step to explore · Use arrow keys

These are simple illustrations, not exact pictures of molecules. Arrows connect ideas; they do not prove that every step happens in people, that a treatment works, or that it is safe.

1 / 4

STEP 01 / IN PLAIN LANGUAGE

One molecule, two targets

Tirzepatide acts on receptors for two hormones called GIP and GLP-1. Approved medicines containing it have specific uses and safety rules.

Based on: How the medicine interacts with the body

What this does not prove: Being listed here does not mean a medicine is right for you or offered by the practice.

Want the scientific detail?

Tirzepatide

Tirzepatide is a peptide agonist with activity at GIP and GLP-1 receptors. Its approved finished products have specific labeling.

Evidence context: Drug pharmacology

Important limit: Catalog inclusion does not imply that a product is suitable or offered by the practice.

Keep the distinction: Two targets do not mean twice the benefit, or that medicines should be combined.
Read the full molecule profile Follow the metabolism trail

A dated view of the research

Selected sources checked:

This date tells you when the linked sources were checked. It does not mean every new study or every part of a medicine’s safety label was reviewed. This site does not monitor changes or update itself automatically. Research and regulations can change. Follow the official source links to check for later information.

See 2 sources & what was checked

Official product database · Original approval: November 8, 2023

Drugs@FDA: Zepbound approval record

Product identity and approval history checked; use the official record for label changes. Not a complete label review.

Scientific detail is optional. Publication dates tell you when studies appeared; the source-check date tells you when these links and selected information were checked. This is a selected reading list, not a review of every study or an independent medical endorsement.

Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.